Hyperlipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of morbidity and mortality among Veterans and civilians. Approximately 10% of U.S. adults have elevated total cholesterol levels, yet many with cardiovascular risk remain untreated or undertreated. In response, the Department of Veterans Affairs (VA) and the Department of Defense (DoD) collaboratively updated the Clinical Practice Guideline on Lipid Management for Cardiovascular Disease Risk Reduction to provide standardized, evidence-based recommendations aimed at reducing cardiovascular risk and improving long-term outcomes. An interdisciplinary panel of practicing clinicians led the development of the guideline, adhering to the Institute of Medicine’s standards for trustworthy guidelines. The panel systematically reviewed 461 full-length articles, evaluating the benefits and harms of lipid-lowering therapies, patient preferences, and applicability across diverse populations and care settings. This poster highlights key components of the updated guideline, including risk stratification tools, lipid screening recommendations, and treatment thresholds. Emphasis is placed on lifestyle interventions, shared decision making and in appropriate patients integrating statin therapy, non-statin agents into individualized care plans. The guideline also underscores the importance of ongoing research and real-world implementation strategies to optimize lipid management and reduce ASCVD events. By implementing these recommendations, clinicians can deliver consistent, high-quality care that supports the cardiovascular health and operational readiness of Veterans and active-duty service members.